Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 358-363

  Grenache, David G ^a   Heichman, Karen A ^a   Werner, Theresa L ^a   Vucetic, Zivjena ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b FUJIREBIO INC   (Japan)

Author keywords

Adnexal mass; Multi marker test; Ovarian cancer; Sensitivity and specificity

Indexed keywords

ADNEXA DISEASE; ADNEXAL CANCER; ADULT; AGED; ALGORITHM; ARTICLE; BLOOD EXAMINATION; CANCER CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVA1 TEST; OVARY CANCER; PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK OF OVARIAN MALIGNANCY ALGORITHM; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; ADOLESCENT; BLOOD; FEMALE GENITAL SYSTEM; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS;

APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; PREALBUMIN; PROTEIN; TRANSFERRIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADNEXA UTERI; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; APOLIPOPROTEIN A-I; BETA 2-MICROGLOBULIN; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREALBUMIN; PREMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS; SENSITIVITY AND SPECIFICITY; TRANSFERRIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84908231150     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.09.028     Document Type: Article

References (21)

1. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995, 273:491-497.
2. ACOG Committee opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011, 117:742-746.
3. NCCN NCCN Clinical Practice Guidelines for Ovarian Cancer 2008. NCCN Practice Guideline 2001, 1-39.
4. Giede K.C., Kieser K., Dodge J., Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005, 99:447-461.
5. Chan J.K., Kapp D.S., Shin J.Y., et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007, 109:1342-1350.
6. ACOG ACOG practice bulletin. Management of adnexal masses. Obstet Gynecol 2007, 110:201-214.
7. NCCN NCCN Clinical Practice Guidelines in Oncology: ovarian cancer. NCCN guidelines 2014, 1-90.
8. Ueland F.R., Desimone C.P., Seamon L.G., et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011, 117:1289-1297.
9. Bristow R.E., Smith A., Zhang Z., et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol 2013, 128:252-259.
10. Moore R.G., Miller M.C., Disilvestro P., et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011, 118:280-288.
11. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
12. Zhang Z. An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for ovarian cancer: harvesting the power of multiple biomarkers. Rev Obstet Gynecol 2012, 5:35-41.
13. Moore R.G., Mcmeekin D.S., Brown A.K., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46.
14. Moore R.G., Jabre-Raughley M., Brown A.K., et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010, 203:228.e1-228.e6.
15. Ruggeri G., Bandiera E., Zanotti L., et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011, 412:1447-1453.
16. Zhang Z., Bast R.C., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890.
17. Hellstrom I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
18. Moore R.G., Brown A.K., Miller M.C., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008, 110:196-201.
19. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408.
20. Park Y., Lee J.-H., Hong D.J., Lee E.Y., Kim H.-S. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011, 44(10-11):884-888.
21. Clarke C.H., Yip C., Badgwell D., et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011, 122:548-553.